Pharmacological control of progression
Atropine drops are being investigated as a means of inhibiting the progression of myopia. Concentration, tolerance, age and progression are important; the name of the substance is not the name of the product.
It is a muscarinic receptor antagonist. The clinical effect on progression is not limited to merely relaxing accommodation; the mechanisms by which eye growth is regulated remain under investigation.
From Bedrossian's early work, through ATOM and ATOM2, to studies of low LAMP concentrations. Each step changed the question: from whether the effect existed, to the selection of concentration, tolerability, and maintenance of the effect after discontinuation.
Go to full timelineATOM showed slower refractive progression and ocular axis increase with atropine 1% than with placebo.
One randomly selected eye was treated; Asian population. We do not transfer the effects and effectiveness of this concentration directly to low concentrations.
Publication, Authors and RestrictionsATOM2 compared the atropine concentrations of 0,5%, 0,1% and 0,01%; lower concentrations had a milder visual symptom profile.
No parallel placebo arm. The historical placebo with ATOM1 is not an equivalent random comparator.
Publication, Authors and RestrictionsIn LAMP, atropine 0,05% provided greater control of refraction and axis extension than 0,025% and 0,01% in the first year of the study.
The response was concentration dependent; this result does not establish the optimal dose for each child.
Publication, Authors and RestrictionsIn the American PEDIG RCT, atropine 0,01% did not slow progression or axis prolongation relative to placebo.
The result relates to the tested concentration, preparation and population. It does not disprove the effects of all concentrations of atropine.
Publication, Authors and RestrictionsThe review is not a substitute for checking a specific intervention. The publication date and query end date may vary.
IMI 2025 organizes optical, pharmacological, environmental and lighting strategies and the state of research on their effects.
Mature technologies and emerging methods have a different evidence base. The inspection is not an individual clinical eligibility assessment of the child.
Publication, Authors and RestrictionsATOM2 post-discontinuation phases show that the end-of-treatment score alone does not describe the entire pathway. Myopia control also requires a post-intervention evaluation plan.
Pupil dilation, photophobia and difficulty seeing at close range depend, among other things, on: on concentration. Tolerance and course after discontinuation are monitored; concentration and schedule are not selected based on the online table.
LAMP and American PEDIG gave different results for atropine 0,01%. All concentrations should not be averaged to a single "atropine effectiveness" number. ATOM2 did not have a parallel placebo.
According to the ESO/IMI framework, it may be considered in children with progressive myopia after individual risk assessment. The availability and status of a specific preparation should be checked in the current product documentation.
This is a framework for a conversation with a specialist, not an individual treatment plan.
Bedrossian's record from 1971 documents the early stage of research on atropine in myopia.
Verified metadata; no abstract in the register. We do not attribute the numerical effect or the contemporary standard of RCT. This is the oldest verified record for this version of the axis, not a claim of the first ever study.
Publication, Authors and RestrictionsAfter discontinuation of atropine in ATOM2, rebound dependent on the previous concentration was observed.
The post-treatment phase concerns participants in a specific study. It does not designate a universal withdrawal pattern.
Publication, Authors and RestrictionsESO and IMI present a framework for the selection of management, prevention and monitoring of myopia progression.
The guidelines require reference to current knowledge, local availability and the specific patient.
Publication, Authors and Restrictions